Recently, No.1 Hospital Affiliated to ZZU made progress in the Clinical Treatment of Infectious Diseases. The related result, with Dr. Zeng Qinglei as the first author, Prof. Yu Zujiang as corresponding author, was published in a top journal of international Hepatitis, Journal of Hepatology of EASL, entitled “Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study”.

At present, USA has developed DAAs against hepatitis C virus, increasing its curative ratio to nearly 100％. Due to foreign patent protection and research expenses, the cost for every course of treatment is formidably high. Dr. Zeng and Prof. Yu’s research, as the first purely observational real-world research of US-authorized non-patent DAAs against hepatitis C virus, lays a solid foundation for its subsequent extensive use and is a positive thing in uprooting hepatitis C virus. ( translator Song Gencheng)